Company intelligence / Profile preview

Rogne Bioscience

Portola Valley, California, United States

Ownership: Private
Development stage: Other

Overview

Rogne Bioscience is developing RON-2315, a low–molecular weight human peptide derived from chemerin as a topical biologic for psoriasis; preclinical data showed potent inhibition of dermal inflammation in IL‑23–dependent mouse models and regulation of NF‑kB‑p65 and IL‑23 secretion in human dendritic cells, but the program has since been discontinued with no evidence of advancement into clinical trials.[2][3][5][7]

Therapeutic areas: ImmunologyDermatology
Modalities: PeptidesBiologic
Industry: Biotech

Partnerships

Isis Innovation (University of Oxford technology commercialization arm)[2][3][11]

Beyond the preview

Go deeper on Rogne Bioscience.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Rogne Bioscience.

Explore the full profile